SRR934725
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 146.4520367936925
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.400
- NOTCH_SIGNALING+0.387
- PROTEIN_SECRETION+0.387
- CHOLESTEROL_HOMEOSTASIS+0.368
- MITOTIC_SPINDLE+0.366
- ANDROGEN_RESPONSE+0.352
- ADIPOGENESIS+0.321
- MTORC1_SIGNALING+0.296
- FATTY_ACID_METABOLISM+0.279
- BILE_ACID_METABOLISM+0.259
Top 10 suppressed
- KRAS_SIGNALING_DN-0.306
- ANGIOGENESIS-0.271
- SPERMATOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.247
- PANCREAS_BETA_CELLS-0.247
- APICAL_SURFACE-0.232
- COAGULATION-0.134
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.114
- APICAL_JUNCTION-0.100
- INFLAMMATORY_RESPONSE-0.098
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934762 | — | — | 0.906 |
| 2 | 8441B707-EC45-4A38-8B83-99B8D83CCF8B | — | — | 0.874 |
| 3 | SRR934756 | — | — | 0.874 |
| 4 | 10EE3CFC-9230-40BA-9C9F-77949BA763CC | — | — | 0.872 |
| 5 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.870 |
| 6 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.867 |
| 7 | 21D48ADE-2798-4380-999A-9485A70E7D2A | — | — | 0.864 |
| 8 | B7B0DDFA-C204-4F84-A1C5-8F836668B99F | — | — | 0.856 |
| 9 | SRR934820 | — | — | 0.851 |
| 10 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.387 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.387 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.368 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.366 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.352 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.321 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.296 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.279 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.259 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.259 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.249 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.223 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.222 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.192 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.167 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.154 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.154 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.142 | Inavolisib | — uncovered |
| APOPTOSIS | 0.105 | Idelalisib | — uncovered |